Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
IPO Year:
Exchange: NASDAQ
Website: theravance.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
4/12/2024 | $21.00 | Buy | BTIG Research |
1/8/2024 | Outperform → In-line | Evercore ISI | |
5/23/2022 | $12.00 | Outperform | SVB Leerink |
3/2/2022 | $10.00 → $11.00 | Underweight | Morgan Stanley |
2/24/2022 | $8.00 → $12.00 | Buy | HC Wainwright & Co. |
11/5/2021 | $7.00 → $12.00 | Underweight → Neutral | JP Morgan |
9/16/2021 | $14.00 → $10.00 | Underweight | Morgan Stanley |
9/16/2021 | $21.00 → $8.00 | Buy | HC Wainwright & Co. |
9/16/2021 | $29.00 → $10.00 | Outperform | SVB Leerink |
Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously
BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00
Evercore ISI downgraded Theravance Biopharma from Outperform to In-line
SVB Leerink initiated coverage of Theravance Biopharma with a rating of Outperform and set a new price target of $12.00
Morgan Stanley reiterated coverage of Theravance Biopharma with a rating of Underweight and set a new price target of $11.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $12.00 from $8.00 previously
JP Morgan upgraded Theravance Biopharma from Underweight to Neutral and set a new price target of $12.00 from $7.00 previously
Morgan Stanley reiterated coverage of Theravance Biopharma with a rating of Underweight and set a new price target of $10.00 from $14.00 previously
HC Wainwright & Co. reiterated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $8.00 from $21.00 previously
SVB Leerink reiterated coverage of Theravance Biopharma with a rating of Outperform and set a new price target of $10.00 from $29.00 previously
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approvedNow expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months laterQ2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024Q2 2024 ending cash balance of $96.1 millionDUBLIN, Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced
DUBLIN, July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, u
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 20231Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvementContinued progress for ampreloxetine CYPRESS enrollmentVirtual ampreloxetine KOL event scheduled for May 23, 2024Q1 2024 ending cash balance of $100 millionDUBLIN, May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the first quarter of 2024. "Building
DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, und
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million1Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 millionGAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million2Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended Dece
DUBLIN, Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on Monday, February 26, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.
Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and 53%, Y/Y, respectively2PIFR-2 enrollment nearing completion; top-line data in late Q4 2023, with disclosure anticipated in January 2024Company expects to complete $325 million capital return program by year-end, having returned $80.5 million via share repurchases during Q2 2023 and $263.8 million since inception through quarter endDUBLIN, Aug. 7, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational result
DUBLIN, July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, u
Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs2CYPRESS Phase 3 study of ampreloxetine recruiting; anticipate completing enrollment during H2 2024On track to complete $325 million capital return program by year-end; completed $215 million of share repurchases from inception through 4/30/23Jim Kelly, Managing Director at Weiss Asset Management, joins Board of DirectorsDUBLIN, May 8, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financ
DUBLIN, April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, unde
DUBLIN, Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma Theravan
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approvedNow expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months laterQ2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024Q2 2024 ending cash balance of $96.1 millionDUBLIN, Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced
DUBLIN, July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To listen to the webcast or schedule meetings with management, please contact your BTIG representative or email [email protected]. About Theravance Biopharma Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference®
DUBLIN, July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its second quarter 2024 financial results and provide a business update after market close on Monday, August 5, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, u
Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 20231Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvementContinued progress for ampreloxetine CYPRESS enrollmentVirtual ampreloxetine KOL event scheduled for May 23, 2024Q1 2024 ending cash balance of $100 millionDUBLIN, May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the first quarter of 2024. "Building
DUBLIN, May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma Theravance Biopharma, I
DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, und
DUBLIN, April 10, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (the "Company") (NASDAQ:TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to 11:30 AM ET, featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH. To register, click here.
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million1Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 millionGAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million2Completed $325 million capital return program, reducing shares outstanding by 37% Ampreloxetine investor event planned for Q2 2024DUBLIN, Feb. 26, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended Dece
DUBLIN, Feb. 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5 at 10:30 am ET (7:30 am PT/3:30 pm GMT). Members of Theravance Biopharma senior management will be hosting one on one meetings at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biop
SC 13G - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13D/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13D/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13D - Theravance Biopharma, Inc. (0001583107) (Subject)
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si
PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022. His appointment brings the company's board of directors to ten members. "Eran has a proven track record taking high-growth healthcare businesses to the next level and delivering superior results," said William Feehery, Ph.D., CEO of Certara. "Certara is excited to have someone of his caliber and experience join the board. I look forward to Eran's contribution in guiding us as we grow our impact by informing critical decisions in drug development with biosimulation, technology and
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
DEF 14A - Theravance Biopharma, Inc. (0001583107) (Filer)
10-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Mama’s Creations Inc (NASDAQ:MAMA) fell in today's pre-market trading following first-quarter results. Mama's Creations posted downbeat earnings for its first quarter, while sales topped estimates. Mama’s Creations shares declined 3% to $6.97 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. U-BX Technology Ltd. (NASDAQ:UBXG) shares dipped 15.4% to $9.83 in pre-market trading after jumping 21% on Tuesday. Ferrovial SE (NASDAQ:FER) shares declined 5.8% to $38.99 in pre-market trading after gaining 5% on
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 million which beat the analyst consensus estimate of $13.963 million by 3.87 percent. This is a 39.22 percent increase over sales of $10.417 million the same period last year.
BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $21.
Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Monday, February 26, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Theravance Biopharma missed estimated earnings by -13.0%, reporting an EPS of $-0.17 versus an estimate of $-0.15. Revenue was up $2.92 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.04 which was followed by a 5.0% increase in the share price the next day. Here's a look at Theravance Biopharma's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.21 -0.16 -0.26 -0.17 EPS Actual -0.17 -0.13 -0.24 -0.21 Revenue Estimate 15.00
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. The company reported quarterly sales of $17.57 million which missed the analyst consensus estimate of $17.68 million by 0.67 percent. This is a 19.91 percent increase over sales of $14.65 million the same period last year.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. • Krystal Biotech (NASDAQ:KRYS) is estimated to report quarterly loss at $0.37 per share on revenue of $28.61 million. • Li Auto (NASDAQ:LI) is estimated to report quarterly earnings at $0.29 per share on revenue of $5.48 billion. • Clear Channel Outdoor (NYSE:CCO) is expected to report quarterly earnings at $0.04 per share on revenue of $610.14 million. • Lincoln Educational Servs (NASDAQ:LINC) is expected to report quarterly earnings at $0.27 per share on revenue of $96.20 million. • BioCryst Pharma (NASDAQ:BCRX) is projected to re